
    
      -  to determine the objective response rate and estimate the time to progression of
           combination gemcitabine, capecitabine, and bevacizumab in patients with metastatic clear
           cell renal cell cancer;

        -  to determine survival of combination gemcitabine, capecitabine, and bevacizumab in
           patients with metastatic cell renal cell cancer;

        -  to determine the toxicity of combination gemcitabine, capecitabine, and bevacizumab in
           patients with metastatic renal cell cancer;

        -  to collect baseline serum and plasma samples for exploration of possible prognostic and
           predictive markers
    
  